-
Mashup Score: 2Nicholas Turner on High-Risk Early-Stage Breast Cancer Profiling Primary Tumors - The ASCO Post - 6 month(s) ago
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Foundation Trust, and the Institute of Cancer Research, London, discusses the monarchE trial, which evaluated molecular profiling of archived primary tumor tissue from patients with hormone receptor–positive, HER2-negative, node-positive, high-risk early-stage breast cancer and its potential association with clinical outcomes. Adjuvant abemaciclib plus endocrine therapy (ET) maintained invasive disease–free survival benefit compared with ET
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Aditya Bardia on HR-Positive HER2-Negative Advanced Breast Cancer Datopotamab Deruxtecan vs Chemotherapy - The ASCO Post - 6 month(s) ago
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses updated phase III r esults from the TROPION-Breast01 study. The data showed an improvement in progression-free survival with datopotamab deruxtecan compared with investigator’s choice of chemotherapy across all subgroups of patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received one to two prior lines of chemotherapy (Abstract GS02-01). Senthil Damodaran, MD, PhD, of
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Combining Ribociclib With Hormone Therapy Improves Patient Outcomes in Early-Stage Breast Cancer NATALEE - The ASCO Post - 6 month(s) ago
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease–free survival benefits in patients with early-stage hormone receptor–positive, HER2-negative breast cancer at risk of disease recurrence. Results from the phase III NATALEE trial, led by researchers at The University of Texas MD Anderson Cancer Center, were presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS 3-03). Patients who received the combination regimen experienced significantly
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Genetic Characteristics of HER2-Low Advanced Breast Cancers May Guide Treatment Selection - The ASCO Post - 6 month(s) ago
Researchers have revealed significant differences in the genetic characteristics of HER2-low advanced breast cancers, which may lead to the development of novel therapeutics for patients, according to recent findings presented by Kahn et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PO4-15-08). The targeted antibody-drug conjugate fam-trastuzumab deruxtecan-nxki has be en approved for the treatment of HER2-low advanced breast cancers. “If genomic alterations that are particular to HER2-low
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Using Estrogen Levels to Predict Who May Benefit From Preventive Treatment With Anastrozole - The ASCO Post - 6 month(s) ago
Investigators have found that estrogen levels measured through blood tests may be predictive of which individuals at high risk of breast cancer will benefit from aromatase inhibitors, according to a recent study presented by Cuzick et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PS10-03) and simultaneously published in The Lancet Oncology. These findings may lead to improved strategies for identifying postmenopausal patients who may respond positively to therapy. About one-seventh of
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
A novel risk model may be effective at using baseline sociodemographic and financial measures to predict the risk of long-term aromatase inhibitor nonadherence among patients with breast cancer, according to new findings presented by Hershman et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PS04-08). About two-thirds of the patients who receive treatment for breast cancer have hormone receptor–positive disease and are often prescribed aromatase inhibitors to reduce hormone production.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Novel Targeted Therapies May Benefit Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer - The ASCO Post - 6 month(s) ago
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor–positive/HER2-negative breast cancer. The data were shared in oral presentations at the 2023 San Antonio Breast Cancer Symposium. According to the National Cancer Institute, hormone receptor–positive/HER2-negative breast cancer is the predominant breast cancer subtype in the
Source: www.ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Nicholas C. Turner, MD, PhD, on High-Risk Early-Stage Breast Cancer: Profiling Primary Tumors https://t.co/VvzYITpLLF #bcsm #breastcancer #oncology #SABCS23 @SABCSSanAntonio @ICR_London @royalmarsdenNHS